{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:12:58Z","timestamp":1789708378592,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"am","delay-in-days":360,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.lungcan.2024.107928","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T17:04:56Z","timestamp":1723568696000},"page":"107928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma"],"prefix":"10.1016","volume":"195","author":[{"given":"Aaron S.","family":"Mansfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Vivien Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiven","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyudmila A.","family":"Bazhenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Forde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dizona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza C.","family":"Villaruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne M.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedy L.","family":"Kindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Koczywas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Mikula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Adjei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Moscow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.lungcan.2024.107928_b0005","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2024.107928_b0010","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical Efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"10272","key":"10.1016\/j.lungcan.2024.107928_b0015","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.lungcan.2024.107928_b0020","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde","year":"2021","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2024.107928_b0025","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol."},{"issue":"10419","key":"10.1016\/j.lungcan.2024.107928_b0030","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2024.107928_b0035","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","author":"Butterfield","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107928_b0040","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","article-title":"Development of immunotherapy combination strategies in cancer","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.lungcan.2024.107928_b0045","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107928_b0050","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107928_b0055","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.lungcan.2024.107928_b0060","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1158\/1535-7163.MCT-10-0644","article-title":"Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules","volume":"9","author":"Lopus","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107928_b0065","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"PNAS"},{"issue":"11","key":"10.1016\/j.lungcan.2024.107928_b0070","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res."},{"issue":"34","key":"10.1016\/j.lungcan.2024.107928_b0075","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin immunotherapy for cancer: ready for prime time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.107928_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2023.100756","article-title":"Targeting mesothelin in cancer","volume":"31","author":"Elbi","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.lungcan.2024.107928_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.008","article-title":"Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?","volume":"102","author":"Gerber","year":"2016","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107928_b0090","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107928_b0095","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"16","key":"10.1016\/j.lungcan.2024.107928_b0100","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107928_b0105","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1470-2045(22)00061-4","article-title":"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial","volume":"23","author":"Kindler","year":"2022","journal-title":"Lancet Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2024.107928_b0110","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/cncr.28875","volume":"120","author":"Hassan","year":"2014","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.lungcan.2024.107928_b0115","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1158\/1078-0432.CCR-07-1035","article-title":"Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts","volume":"13","author":"Zamboni","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.lungcan.2024.107928_b0120","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-023-02452-y","article-title":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1\/2 trial interim results","volume":"29","author":"Hassan","year":"2023","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.lungcan.2024.107928_b0125","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7\u2013H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107928_b0130","article-title":"The predictive and prognostic nature of programmed death-ligand 1 in malignant pleural mesothelioma: a systematic literature review","volume":"3","author":"Mansfield","year":"2022","journal-title":"JTO Clin Res Rep"},{"issue":"5","key":"10.1016\/j.lungcan.2024.107928_b0135","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107928_b0140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-21-1181","article-title":"Phase I\/IIa Trial of BMS-986148, an Anti-mesothelin antibody-drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors","volume":"28","author":"Rottey","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.lungcan.2024.107928_b0145","doi-asserted-by":"crossref","first-page":"5915","DOI":"10.1158\/0008-5472.CAN-11-0466","article-title":"Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding","volume":"71","author":"Zhang","year":"2011","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.lungcan.2024.107928_b0150","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2202439119","article-title":"Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin","volume":"119","author":"Liu","year":"2022","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.lungcan.2024.107928_b0155","doi-asserted-by":"crossref","first-page":"2233401","DOI":"10.1080\/2162402X.2023.2233401","article-title":"An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin","volume":"12","author":"Snell","year":"2023","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.lungcan.2024.107928_b0160","article-title":"Importance and considerations of antibody engineering in antibody-drug conjugates development from a clinical pharmacologist's perspective","volume":"10","author":"Lucas","year":"2021","journal-title":"Antibodies (Basel)"},{"issue":"1","key":"10.1016\/j.lungcan.2024.107928_b0165","article-title":"Factors affecting the pharmacology of antibody-drug conjugates","volume":"7","author":"Lucas","year":"2018","journal-title":"Antibodies (Basel)"},{"issue":"3","key":"10.1016\/j.lungcan.2024.107928_b0170","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10928-021-09799-0","article-title":"Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate","volume":"49","author":"Pouzin","year":"2022","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107928_b0175","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00280-021-04250-0","article-title":"Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology","volume":"87","author":"Liu","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107928_b0180","article-title":"Pharmacologic considerations in the disposition of antibodies and antibody-drug conjugates in preclinical models and in patients","volume":"8","author":"Lucas","year":"2019","journal-title":"Antibodies (Basel)"},{"issue":"Suppl 2","key":"10.1016\/j.lungcan.2024.107928_b0185","first-page":"S85","article-title":"Effect of obesity on the pharmacokinetics and pharmacodynamics of anticancer agents","volume":"63","author":"Zamboni","year":"2023","journal-title":"J. Clin. Pharmacol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224004628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224004628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T05:50:05Z","timestamp":1726033805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224004628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":37,"alternative-id":["S0169500224004628"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107928","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107928","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107928"}}